Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medroxyprogesterone-induced endocrine alterations after menopause.

Tarja Saaresranta1, Kerttu Irjala, Päivi Polo-Kantola

  • 1Department of Pulmonary Medicine, Turku University Central Hospital, Finland. tarja.saaresranta@tyks.fi

Menopause (New York, N.Y.)
|June 26, 2002
PubMed
Summary

Short-term medroxyprogesterone acetate (MPA) significantly impacts hormone levels in postmenopausal women, decreasing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) while increasing insulin-like growth factor-I (IGF-I). These endocrine changes persist for weeks after treatment cessation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nausea and vomiting of pregnancy in relation to fear of childbirth: Evidence from a Finnish cohort.

Acta obstetricia et gynecologica Scandinavica·2026
Same author

Maternal fragmented sleep in late pregnancy is associated with higher birthweight.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Disrupted fluid homeostasis in patients with post-Covid-19 syndrome - a case series.

Frontiers in endocrinology·2026
Same author

Is addressing patients' sexual problems inconvenient? A study on barriers to physicians' self-reported competence.

The journal of sexual medicine·2026
Same author

Changes in female sexual function during the retirement transition.

Menopause (New York, N.Y.)·2026
Same author

Transdermal estradiol spray in Nordic menopausal women: real-world patient outcomes.

Climacteric : the journal of the International Menopause Society·2026

Area of Science:

  • Endocrinology
  • Pharmacology
  • Menopause Research

Background:

  • Postmenopausal women with mild nocturnal hypoxemia may benefit from respiratory stimulants.
  • Medroxyprogesterone acetate (MPA) is a progestogen with potential endocrine effects.
  • Understanding MPA's impact on hormone levels is crucial for clinical interpretation.

Purpose of the Study:

  • To assess the endocrine responses to short-term medroxyprogesterone acetate (MPA) therapy.
  • To evaluate MPA's effects as a respiratory stimulant in postmenopausal women.
  • To determine the duration of MPA's influence on key hormone concentrations.

Main Methods:

  • An open-label trial involving 8 postmenopausal women.
  • 14-day administration of medroxyprogesterone acetate (60 mg daily).

Related Experiment Videos

  • Serum hormone levels (FSH, LH, estradiol, progesterone, IGF-I) measured at baseline, during MPA treatment, and 3 weeks post-treatment.

    • Main Results:

    • MPA significantly decreased follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels.
    • Insulin-like growth factor-I (IGF-I) levels showed a significant increase during MPA treatment.
    • Suppressed FSH and LH levels persisted for 3 weeks after MPA cessation, while IGF-I returned to baseline.

    Conclusions:

    • Two weeks of daily MPA (60 mg) induces immediate and sustained endocrine changes.
    • Effects on FSH and LH last up to 3 weeks post-treatment.
    • Hormone assessments after progestogen therapy require consideration of these prolonged MPA-induced effects.